Audrey Cacaly discusses Forbion’s record fundraising and investment strategy
In an interview with BiotechFinances, Audrey Cacaly, Principal at Forbion, discusses the firm’s €2.3 billion fundraising across Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII. The raise marks Forbion’s largest to date and brings its assets under management to approximately €7.5 billion.
The conversation explores the track record and investment strategy behind Forbion’s growth, and the firm’s highly selective approach to investing. With significant capital to deploy, Forbion remains focused on identifying promising biotech companies where its experience can support ambitious teams and help advance important medicines.